Clik here to view.
武田同意以8.25亿美元向Hypera Pharma出让拉丁美洲部分非处方和非核心资产
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天宣布，其已达成一项协议，将以8.25亿美元总价值将其位于拉丁美洲的专有部分非核心产品组合出让给在品牌处方、消费者健康和品牌仿制药领域处于领先地位的巴西最大制药公司Hypera S.A. (“Hypera...
View ArticleClik here to view.
Clik here to view.
Takeda Completes Sale of Select OTC and Non-Core Assets to STADA
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to STADA...
View ArticleClik here to view.
武田收到CHMP同意ALUNBRIG® (brigatinib)用于ALK+非小细胞肺癌一线治疗的肯定意见
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited)(TSE:4502/NYSE:TAK)今天宣布，欧洲药品管理局(EMA)人用药品委员会(CHMP)接纳了一项肯定意见，推荐核准ALUNBRIG...
View ArticleClik here to view.
First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL®...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
武田薬品、ALK陽性非小細胞肺がんのファーストライン治療薬としてのALUNBRIG®（ブリガチニブ）に対するCHMPの肯定的見解を受領
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
拓臻生物将在2020亚太肝脏研究学会年会上发表其候选药物 SSAO激动剂TERN-201临床Ⅰ期研究数据
美国加州福斯特城与中国上海 Terns Pharmaceuticals 拓臻生物 —...
View ArticleClik here to view.
Terns Pharmaceuticals to Present Data from an Ongoing Phase 1 Clinical Trial...
FOSTER CITY, Calif. & SHANGHAI Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis...
View ArticleClik here to view.
TÜV莱茵推出Eyesafe显示标准，新要求引导行业保障用户眼部健康
上海 (美国商业资讯)-国际独立第三方检测、检验和认证机构德国莱茵TÜV集团（以下简称“TÜV莱茵”）宣布推出基于临床健康和安全研究的Eyesafe显示标准（Eyesafe Display...
View ArticleClik here to view.
Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for...
NEW YORK & CAMBRIDGE, Mass. & ROTTERDAM, Netherlands & SUZHOU, China Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to...
View ArticleClik here to view.
Terns PharmaceuticalsがNASH治療薬として開発中のSSAO阻害薬TERN-201の進行中の第1相臨床試験データを発表へ
米カリフォルニア州フォスターシティ & 上海 （ビジネスワイヤ） — 非アルコール性脂肪肝炎（NASH）とがんの革新的治療薬の創薬と開発に傾注する世界的バイオ製薬会社のTerns Pharmaceuticals,...
View ArticleClik here to view.
TÜV Rheinland Launches Eyesafe Display Standard, New Requirements Guide...
SHANGHAI The international independent third-party testing, inspection, and certification organization, TÜV Rheinland Group, has announced the launch of the Eyesafe Display Standard. It is based on...
View ArticleClik here to view.
TÜV Rheinland Launches Eyesafe Display Standard, New Requirements Guide...
SHANGHAI The international independent third-party testing, inspection, and certification organization, TÜV Rheinland Group, has announced the launch of the Eyesafe Display Standard. It is based on...
View ArticleClik here to view.
Notice of Capital and Business Alliance Between Heartseed and MEDIPAL HOLDINGS
TOKYO Tokyo-based Heartseed Inc. (“Heartseed”), a Keio University-originated biotechnology company developing induced pluripotent stem cell (iPSC)-derived cardiac regenerative medicine, and MEDIPAL...
View ArticleClik here to view.
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition...
View ArticleClik here to view.
2万1848人の高リスクPCI患者を対象とした研究でPVAD（Impella）使用患者での死亡／合併症リスク低減を実証
米マサチューセッツ州ダンバース （ビジネスワイヤ） — 経皮的左室補助装置（PVAD /...
View ArticleClik here to view.
患者安全运动基金会任命新董事长；宣布目标是在2030年之前实现可预防的患者死亡为零
加州尔湾 (美国商业资讯)–患者安全运动基金会(Patient Safety Movement Foundation, PSMF)是一家全球性非营利组织，致力于联合医疗保健生态系统的参与者，识别导致患者死亡的挑战，并创建可减少此类死亡的可付诸行动的解决方案。该基金会欣然宣布任命新董事长Michael A.E. Ramsay, MD,...
View ArticleClik here to view.
武田提供3期TOURMALINE-MM2试验的更新
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天发布了TOURMALINE-MM2研究的结果，该研究旨在评估不适合移植的多发性骨髓瘤新诊断患者在来那度胺和地塞米松基础上添加NINLARO™...
View ArticleClik here to view.
Clik here to view.
Next-Gen Artificial Intelligence (AI) Company Graphen Monitors Genomic...
NEW YORK Graphen, Inc., a startup building AI solutions inspired by full brain functionality, today announced its AI gene evolution pathway analysis of the virus that causes the Coronavirus disease,...
View Article